Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

New Dosing Option for Bimekizumab Now Commercially Available for PsA, Psoriasis, HS

These findings highlight the value in understanding and recognizing gender differences in patient experiences with hidradenitis suppurativa and their impact on life quality.

Female Patients with HS Face Disproportionate Disease-Related Limitations

Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.

C-Reactive Protein Effective as Biomarker for HS Treated with Adalimumab

In this analysis, a retrospective and multi-center study was conducted to determine any predictors of biological therapy intensification in individuals with HS.

Prior Use of Biologics, Adalimumab Help Predict HS Biologic Treatment Intensification

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

Study Highlights Impact of Smoking on Surgical Outcomes for HS

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

Comorbidities, Social Determinants of Health Influence Hidradenitis Suppurativa, Study Finds

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa. 

Future Research, Opportunities in Hidradenitis Suppurativa

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials. 

Safety Profile of Bimekizumab in Hidradenitis Suppurativa

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Strengths, Limitations of IL-17 A/F Inhibition in Hidradenitis Suppurativa

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa. 

Understanding, Leveraging IL-17 A/F Inhibition with Bimekizumab in HS

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.